$PBYI

$10.92 +$0.07 (0.65%) Close

$PBYI Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Company Executives

$PBYI Management Team

Mr. Alan Auerbach

Chairman of the Board

President

Chief Executive Officer

Secretary

Age 55

Compensation $3.970M USD

Sex Male

Mr. Maximo Nougues

Chief Financial Officer

Age 56

Compensation $1.405M USD

Sex Male

Mr. Douglas Hunt

Chief Regulatory Affairs

Medical Affairs

Pharmacovigilance

and Law Officer

Age 60

Compensation $1.218M USD

Sex Male

Mr. Mariann Ohanesian

Investor Relations

Age -

Compensation -

Sex Male

Name / Title	Age	Compensation	Sex
Mr. Alan Auerbach Chairman of the Board President Chief Executive Officer Secretary	55	$3.970M USD	Male
Mr. Maximo Nougues Chief Financial Officer	56	$1.405M USD	Male
Mr. Douglas Hunt Chief Regulatory Affairs Medical Affairs Pharmacovigilance and Law Officer	60	$1.218M USD	Male
Mr. Mariann Ohanesian Investor Relations	-	-	Male

Board of Directors

From the proxy statement filed Apr 28, 2026

Directors

serving now

Independent

7 of 8

stated in the proxy

Average tenure

9.6 years

from year joined

CEO also chairs the board

Yes

Alan H. Auerbach

Director	Age	On board	Independent	Committees	Other public boards	2025 pay
Alan H. Auerbach Board chair, CEO	56	2010 16 years	Not independent	Equity Incentive Committee	None stated	Paid as CEO
Alessandra Cesano	65	2022 4 years	Independent	Research and Development Committee	Summit Therapeutics Inc.	Not stated
Allison Dorval	50	2021 5 years	Independent	Audit Committee	None stated	$155,580
Michael P. Miller	69	2018 8 years	Independent	Compensation Committee	Rigel Pharmaceuticals, Inc.	$158,080
Jay M. Moyes Lead independent director	72	2012 14 years	Independent	Audit Committee · Chair Compensation Committee	SINTX Technologies	$173,080
Adrian M. Senderowicz	62	2015 11 years	Independent	Nominating and Corporate Governance Committee Research and Development Committee · Chair	None stated	$165,580
Brian Stuglik	66	2020 6 years	Independent	Compensation Committee · Chair Research and Development Committee	Verastem, Inc.	Not stated
Troy E. Wilson	57	2013 13 years	Independent	Audit Committee Nominating and Corporate Governance Committee · Chair Research and Development Committee	Kura Oncology, Inc.	Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed Apr 28, 2026 describes a review policy but reports no transactions.

Read the policy in the proxy

Comments

Company Executives

$PBYI Management Team

Mr. Alan Auerbach

Mr. Maximo Nougues

Mr. Douglas Hunt

Mr. Mariann Ohanesian

Board of Directors

Related-party transactions

No related-party transactions disclosed